Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 1
2000 2
2001 2
2002 2
2003 3
2004 1
2005 3
2006 7
2007 2
2008 6
2009 7
2010 7
2011 10
2012 15
2013 17
2014 18
2015 29
2016 34
2017 15
2018 27
2019 30
2020 41
2021 44
2022 40
2023 54
2024 52
2025 44
2026 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

464 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Chapari-Ilkhchi
Page 1
Antibody-Drug Conjugates in Gynecologic Cancer.
Karpel HC, Powell SS, Pothuri B. Karpel HC, et al. Am Soc Clin Oncol Educ Book. 2023 May;43:e390772. doi: 10.1200/EDBK_390772. Am Soc Clin Oncol Educ Book. 2023. PMID: 37229642 Free article. Review.
In ovarian cancer, mirvetuximab soravtansine, an ADC targeting alpha-folate receptor (FRalpha), received US Food and Drug Administration (FDA) accelerated approval in November 2022 after data from the single-arm phase III SORAYA trial. A second ADC targeting FRalpha, STRO- …
In ovarian cancer, mirvetuximab soravtansine, an ADC targeting alpha-folate receptor (FRalpha), received US Food and Drug Administration (FD …
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study.
Matulonis UA, Lorusso D, Oaknin A, Pignata S, Dean A, Denys H, Colombo N, Van Gorp T, Konner JA, Marin MR, Harter P, Murphy CG, Wang J, Noble E, Esteves B, Method M, Coleman RL. Matulonis UA, et al. J Clin Oncol. 2023 May 1;41(13):2436-2445. doi: 10.1200/JCO.22.01900. Epub 2023 Jan 30. J Clin Oncol. 2023. PMID: 36716407 Free PMC article. Clinical Trial.
Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate targeting folate receptor alpha (FRalpha). SORAYA is a single-arm, phase II study evaluating efficacy and safety of MIRV in patients with PROC. METHODS: SORAYA enrolled FRalpha-high patients with PROC wh …
Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate targeting folate receptor alpha (FRalpha). SORAYA is a single-arm, pha …
Harnessing intestinal tryptophan catabolism to relieve atherosclerosis in mice.
Chajadine M, Laurans L, Radecke T, Mouttoulingam N, Al-Rifai R, Bacquer E, Delaroque C, Rytter H, Bredon M, Knosp C, Vilar J, Fontaine C, Suffee N, Vandestienne M, Esposito B, Dairou J, Launay JM, Callebert J, Tedgui A, Ait-Oufella H, Sokol H, Chassaing B, Taleb S. Chajadine M, et al. Nat Commun. 2024 Jul 29;15(1):6390. doi: 10.1038/s41467-024-50807-x. Nat Commun. 2024. PMID: 39080345 Free PMC article.
Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine.
Hendershot A, Slabaugh M, Riaz KM, Moore KN, O'Malley DM, Matulonis U, Konecny GE. Hendershot A, et al. Gynecol Oncol Rep. 2023 Feb 28;47:101155. doi: 10.1016/j.gore.2023.101155. eCollection 2023 Jun. Gynecol Oncol Rep. 2023. PMID: 37102083 Free PMC article. Review.
Pooled safety analysis of 464 MIRV-treated patients across 3 trials, including the phase 2 SORAYA study, found that 50% of patients had 1 ocular AEs of interest (AEIs) of blurred vision or keratopathy, the majority being grade 2. ...
Pooled safety analysis of 464 MIRV-treated patients across 3 trials, including the phase 2 SORAYA study, found that 50% of patients h …
Conflict of Interest Disclosures.
[No authors listed] [No authors listed] Global Spine J. 2025 May;15(2_suppl):793S-822S. doi: 10.1177/21925682251336882. Epub 2025 May 21. Global Spine J. 2025. PMID: 40397527 Free PMC article. No abstract available.
Mirvetuximab soravtansine: current and future applications.
Kong B, Zheng W. Kong B, et al. J Hematol Oncol. 2025 Mar 18;18(1):33. doi: 10.1186/s13045-025-01686-2. J Hematol Oncol. 2025. PMID: 40102896 Free PMC article. Review.
Mirvetuximab soravtansine (MIRV), an antibody-drug conjugate targeting folate receptor alpha (FRalpha), has demonstrated promising efficacy in platinum-resistant OEC, particularly in high FRalpha-expressing populations, as evidenced by key clinical trials such as FORWARD I, FORWA …
Mirvetuximab soravtansine (MIRV), an antibody-drug conjugate targeting folate receptor alpha (FRalpha), has demonstrated promising efficacy …
Dendrimer Prodrugs.
da Silva Santos S, Igne Ferreira E, Giarolla J. da Silva Santos S, et al. Molecules. 2016 May 31;21(6):686. doi: 10.3390/molecules21060686. Molecules. 2016. PMID: 27258239 Free PMC article. Review.
Folate Receptor Alpha in Advanced Epithelial Ovarian Cancer: Diagnostic Role and Therapeutic Implications of a Clinically Validated Biomarker.
Zannoni GF, Santoro A, d'Amati A, D'Alessandris N, Scaglione G, Padial Urtueta B, Valente M, Narducci N, Addante F, Spadola S, Bragantini E, Angelico G. Zannoni GF, et al. Int J Mol Sci. 2025 May 29;26(11):5222. doi: 10.3390/ijms26115222. Int J Mol Sci. 2025. PMID: 40508029 Free PMC article. Review.
An immunohistochemical (IHC) evaluation of FRalpha expression using the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay is now approved as a companion diagnostic for selecting patients eligible for mirvetuximab soravtansine, an FRalpha-targeted antibody-drug conjugate. Clinical trials such …
An immunohistochemical (IHC) evaluation of FRalpha expression using the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay is now approved as a companion …
Niacin.
Djadjo S, Bajaj T. Djadjo S, et al. 2023 Mar 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–. 2023 Mar 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–. PMID: 31082080 Free Books & Documents.
Treatment of hypertension in patients 80 years of age or older.
Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ; HYVET Study Group. Beckett NS, et al. N Engl J Med. 2008 May 1;358(18):1887-98. doi: 10.1056/NEJMoa0801369. Epub 2008 Mar 31. N Engl J Med. 2008. PMID: 18378519 Free article. Clinical Trial.
464 results